Effect Of Ticagrelor On Serum Uric Acid And Prognosis In Patients With Acute Coronary Syndrome

Objectives In order to compare the changes of serum uric acid(SUA)before and after administration of ticagrelor,retrospective study was conducted on the clinical data of acute coronary syndrome(ACS)patients treated with aspirin combined with ticagrelor in the Department of Cardiovascular of Hebei General Hospital.Our objective was to investigate the effect of ticagrelor on SUA level and prognosis in patients with ACS.Methods This study applied Hebei General Hospital system and outpatient service system from March 2018 to January 2020 in the hospital to select 204 cases of patients hospitalized in the cardiology department with ACS.According to the patients with oral dual antiplatelet double antiplatelet therapy(DAPT),scheme was divided into 100 mg oral aspirin once-daily combination with 90 mg ticagrelor orally group of 84 cases of twice daily and 100 mg oral aspirin once-daily combined clopidogrel 75 mg orally oncedaily group 120 cases.The aspirin combined with ticagrelor group was selected as the research object,and the SUA level of ticagrelor group before oral administration was taken as the basic control.The SUA value of ticagrelor group before medication and 1 month after medication were collected and compared seriously.Depending on whether SUA is elevated after taking the drug for a month,the patients of ticagrelor group were divided into after treatment for 1 month elevated SUA group of 57 cases(observation group),after treatment for 1 month no elevated SUA group of 27 cases(control group).The basic situation of the two groups were compared at great length,which included gender,age,height,weight,smoking history,the types of ACS,hospitalization days,body mass index(BMI),smoking history,hospitalization days,hypertension,history of diabetes,history of stroke,history of hyperlipidemia,drug combination,neutrophils(NE)、platelet(PLT)、hemoglobin(HGB)、total cholesterol(TC)、triglycerides(TG)、low density lipoprotein cholesterol(LDL-C)、high density lipoprotein cholesterol(HDL-C)、alanine aminotransferase(ALT)、 creatine kinase isoenzyme(CK-MB)、 serum creatinine(Scr)、left ventricular ejection fraction(LVEF)、left ventricular end systolic diameter(LVEDD).The patients were followed up by telephone and outpatient service for about 1 year.The end events were major adverse cardiovascular(MACE)which included cardiovascular death,heart failure,recurrent non-fatal myocardial infarction,unstable angina(UA),malignant arrhythmia,stent thrombosis and adverse drug reaction(breath with difficulty and bleeding events including nasal mucosa hemorrhage,gum bleeding,skin ecchymosis and alimentary tract hemorrhage).Results 1 The SUA of patients before ticagrelor was(330.79±95.33)umol/L and after 1month of ticagrelor was(363.15±112.53)umol/L,with statistical difference compared with that before ticagrelor(P=0.001).2 There was no statistical difference in the basic information between the control group and the observation group(P>0.05).3 In the comparison of MACE,the results showed that the incidence of MACE events in the observation group was slightly higher than that in the control group(24.5% vs 22.2%),however,the difference was not statistically significant(P=0.814).4 In the comparison of adverse reactions,the results showed that the observation group was slightly higher than the control group(21.0% vs 18.5%),however,the difference was not statistically significant(P=0.787).Conclusions 1 Ticagrelor had an effect on SUA level in patients with ACS.2 The increase of SUA level in ACS patients induced by ticagrelor had no significant correlation with prognosis.Figure 1;Table 5;Reference 250...